News
Biostat Research and Development Center has signed an agreement with a pharmaceutical company Stallergenes Greer to carry out a medical experiment.
The subject of the contract is an epidemiological study that will be conducted in adult allergic patients.
- Biostat will be responsible for the preparation of documentation, obtaining approval from the Bioethics Committee, contracts, monitoring, statistical support, delivery of the eCRF system and management of the study,
- enumerates Edyta Klemba - Pharma Division Director at Biostat Research and Development Center.
Stallergenes Greer is a global pharmaceutical company with a 120-year expertise. It specializes in the diagnosis and treatment of allergies through research, development and commercialization of products and services for respiratory, venom and food allergies.
> Read more: Biostat. Full-service CRO
Cooperation of Biostat and Medinice. Doctors used the CoolCryo system during surgery
Biostat will conduct a non-interventional study for Adamed Pharma
The Supreme Medical Council appreciates the results of BioStat® research on the image of doctors
Summary of the conference called "Clinical trials – news and challenges in 2019"
